Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1708707

USP

Valproic acid

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

2-Propylpentanoic acid, Valproic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule linéaire :
(CH3CH2CH2)2CHCO2H
Numéro CAS:
99-66-1
Poids moléculaire :
144.21
Numéro CE :
202-777-3
Numéro MDL:
MFCD00002672
Code UNSPSC :
41116107
ID de substance PubChem :
329751478
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

valproic acid

Fabricant/nom de marque

USP

Indice de réfraction

n20/D 1.425 (lit.)

Point d'ébullition

220 °C (lit.)

Densité

0.9 g/mL at 25 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CCCC(C(O)=O)CCC

InChI

1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)

Clé InChI

NIJJYAXOARWZEE-UHFFFAOYSA-N

Informations sur le gène

human ... ALDH5A1(7915)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Valproic acid USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Divalproex Sodium
  • Divalproex Sodium Delayed-Release Capsules
  • Divalproex Sodium Delayed-Release Tablets
  • Divalproex Sodium Extended-Release Tablets
  • Valproate Sodium Injection
  • Valproic Acid
  • Valproic Acid Capsules

Actions biochimiques/physiologiques

Anticonvulsant that also has efficacy as a mood stabilizer in bipolar disorder

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazardCorrosionExclamation mark
GHS08,GHS05,GHS07

Mention d'avertissement

Danger

Mentions de danger

H302,H315,H318,H360FD

Classification des risques

Acute Tox. 4 Oral - Eye Dam. 1 - Repr. 1A - Skin Irrit. 2

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

231.8 °F - closed cup

Point d'éclair (°C)

111 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 10

1 of 10

Sodium valproate British Pharmacopoeia (BP) Reference Standard

BP452

Sodium valproate

USP

USP

1224201

Divalproex sodium

USP

USP

1708729

Valproic Acid Related Compound A

Valpromide ≥97% (NMR)

Sigma-Aldrich

V3640

Valpromide

Valnoctamide ≥98% (NMR)

Sigma-Aldrich

V4765

Valnoctamide

Supelco

Supelco

PHR1652

Valproic Acid Related Compound A

Citalopram hydrobromide United States Pharmacopeia (USP) Reference Standard

USP

1134233

Citalopram hydrobromide

Risperidone United States Pharmacopeia (USP) Reference Standard

USP

1604654

Risperidone

Phenytoin European Pharmacopoeia (EP) Reference Standard

P1290000

Phenytoin

Phenytoin United States Pharmacopeia (USP) Reference Standard

USP

1535008

Phenytoin

Mattias Linde et al.
The Cochrane database of systematic reviews, 6(6), CD010611-CD010611 (2013-06-26)
Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an
Ivana Rosenzweig et al.
Neuroscience and biobehavioral reviews, 36(8), 1848-1856 (2012-06-02)
Neuropsychiatric medications that directly alter the epigenome, such as valproic acid, can under certain conditions reactivate critical developmental periods and thus impact adult neuroconnectivity. In animal models valproic acid was shown to inhibit the process of postnatal myelination and to
Florence I Roullet et al.
Neurotoxicology and teratology, 36, 47-56 (2013-02-12)
Valproic acid (VPA) is both an anti-convulsant and a mood stabilizer. Clinical studies over the past 40 years have shown that exposure to VPA in utero is associated with birth defects, cognitive deficits, and increased risk of autism. Two recent
Radu M Nanau et al.
Clinical biochemistry, 46(15), 1323-1338 (2013-06-25)
Valproic acid is a widely-used first-generation antiepileptic drug, prescribed predominantly in epilepsy and psychiatric disorders. VPA has good efficacy and pharmacoeconomic profiles, as well as a relatively favorable safety profile. However, adverse drug reactions have been reported in relation with
Periyasamy Palsamy et al.
Experimental eye research, 121, 26-34 (2014-02-15)
Recent epidemiological studies confirm the prevalence of cataract in epileptic patients. Similarly, the drugs used to treat epilepsy also show the connection with increased cataract formation. In this present study, we investigated the suppression of Nrf2/Keap1 dependent antioxidant protection through
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique